{
    "nct_id": "NCT05118789",
    "official_title": "A Phase 1/2 Study of the Highly Selective ROS1 Inhibitor NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors (ARROS-1)",
    "inclusion_criteria": "1. Age ≥18 years (Cohort 2e only: Age ≥12 years and weighing>40 kg).\n2. Disease Criteria:\n\n   1. Phase 1: Histologically or cytologically confirmed locally advanced or metastatic solid tumor with documented ROS1 rearrangement.\n   2. Phase 2: Cohorts 2a, 2b, 2c and 2d: Histologically or cytologically confirmed locally advanced or metastatic NSCLC with ROS1 rearrangement.\n   3. Phase 2: Cohort 2e: Histologically or cytologically confirmed locally advanced or metastatic solid tumor (other than NSCLC) with ROS1 rearrangement.\n3. Prior anticancer treatment (except cohort 2a).\n4. Phase 1: Must have evaluable disease (target or nontarget) according to RECIST 1.1. Phase 2: Must have measurable disease according to RECIST 1.1.\n5. Adequate baseline organ function and bone marrow reserve.\nHealthy volunteers allowed\nMust have minimum age of 12 Years",
    "exclusion_criteria": "1. Patient's cancer has a known oncogenic driver alteration other than ROS1.\n2. Known allergy/hypersensitivity to excipients of NVL-520.\n3. Major surgery within 4 weeks of first dose of study drug.\n4. Ongoing anticancer therapy.\n5. Actively receiving systemic treatment or direct medical intervention on another therapeutic clinical study.",
    "miscellaneous_criteria": ""
}